Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ)
- PMID: 31193410
- PMCID: PMC6526304
- DOI: 10.1016/j.jdsr.2018.09.002
Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ)
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ), characterized by refractory bone exposure, has recently emerged as a serious side effect of bisphosphonate (BPs) treatment. We discuss novel insights that may help to improve the efficacy of BRONJ treatment and prevention. Our report highlights the following: (1) The presence of exposed bone in patients taking BPs does not necessarily reflect BRONJ, and diagnoses of oral ulceration with bone sequestration and malignancy must be excluded. (2) Osteonecrosis type of BRONJ is difficult to avoid using preventive dental measures alone. However, as with osteomyelitis type of BRONJ, preventive dental measures are indispensable for reducing the risk of secondary infection and disease progression. (3) The importance of tooth extraction as a risk factor for BRONJ among patients taking BPs has been overstated, particularly when they are administered at low doses. Delaying tooth extraction may increase the risk for the onset and progression of osteomyelitic BRONJ. (4) In patients taking low doses of BPs, dental implant surgery is not necessarily contraindicated if there are no other risk factors, such as combined use of corticosteroids or concomitant diabetes. However, the risk of BRONJ due to peri-implantitis must be explained when obtaining patient consent.
Keywords: BRONJ; Bisphosphonates; Jaw; Osteomyelitis; Osteonecrosis; Tooth extraction.
Figures



Similar articles
-
Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update.Odontostomatol Trop. 2013 Jun;36(142):38-46. Odontostomatol Trop. 2013. PMID: 24073539 Review.
-
Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.J Oral Maxillofac Surg. 2009 May;67(5 Suppl):35-43. doi: 10.1016/j.joms.2009.01.003. J Oral Maxillofac Surg. 2009. PMID: 19371813
-
Preexisting Periapical Inflammatory Condition Exacerbates Tooth Extraction-induced Bisphosphonate-related Osteonecrosis of the Jaw Lesions in Mice.J Endod. 2016 Nov;42(11):1641-1646. doi: 10.1016/j.joen.2016.07.020. Epub 2016 Sep 13. J Endod. 2016. PMID: 27637460 Free PMC article.
-
Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy.Acta Medica (Hradec Kralove). 2012;55(3):111-5. doi: 10.14712/18059694.2015.47. Acta Medica (Hradec Kralove). 2012. PMID: 23297518 Review.
-
Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?J Craniomaxillofac Surg. 2015 Jul;43(6):847-54. doi: 10.1016/j.jcms.2015.03.039. Epub 2015 Apr 10. J Craniomaxillofac Surg. 2015. PMID: 25958767
Cited by
-
Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis.Stem Cell Res Ther. 2021 Jul 2;12(1):377. doi: 10.1186/s13287-021-02456-w. Stem Cell Res Ther. 2021. PMID: 34215342 Free PMC article.
-
The Therapeutic Effectiveness Using Fluorescence-Guided Surgery for MRONJ.Biomed Res Int. 2022 Sep 17;2022:1650790. doi: 10.1155/2022/1650790. eCollection 2022. Biomed Res Int. 2022. PMID: 36164452 Free PMC article. Review.
-
Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database.Pharmaceuticals (Basel). 2020 Dec 16;13(12):467. doi: 10.3390/ph13120467. Pharmaceuticals (Basel). 2020. PMID: 33339150 Free PMC article.
-
Assessing dental surgeons' understanding of bisphosphonates: Implications for patient health in oral surgery.Saudi Dent J. 2024 Jan;36(1):180-186. doi: 10.1016/j.sdentj.2023.09.011. Epub 2023 Sep 29. Saudi Dent J. 2024. PMID: 38375400 Free PMC article.
-
Characterization of Mesenchymal Stem Cells Derived from Bisphosphonate-Related Osteonecrosis of the Jaw Patients' Gingiva.Stem Cell Rev Rep. 2022 Jan;18(1):378-394. doi: 10.1007/s12015-021-10241-8. Epub 2021 Sep 22. Stem Cell Rev Rep. 2022. PMID: 34553308 Free PMC article.
References
-
- Yoneda T., Hagino H., Sugimoto T., Ohta H., Takahashi S., Soen S. Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017;35(1):6–19. - PubMed
-
- Khan A.A., Morrison A., Hanley D.A., Felsenberg D., McCauley L.K., O’Ryan F. International task force on osteonecrosis of the jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Mineral Res. 2015;30(1):3–23. - PubMed
-
- Qi W.X., Tang L.N., He A.N., Yao Y., Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19:403–410. - PubMed
-
- Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117. - PubMed
-
- Urade M., Tanaka N., Furusawa K., Shimada J., Shibata T., Kirita T. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg. 2011;69:e364–e371. - PubMed
Publication types
LinkOut - more resources
Full Text Sources